Wednesday, November 6, 2024
HomeTagsRGX-202

RGX-202

REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy

REGENXBIO Inc. announced the clearance of its Investigational New Drug (IND) application by the United States Food and Drug Administration (FDA) to evaluate RGX-202,...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics